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Abstract
The field of proteomics has made leaps and bounds in the last 10 years particularly in the fields of
oncology and cardiovascular medicine. In comparison, neuroproteomics is still playing catch up
mainly due to the relative complexity of neurological disorders. Schizophrenia is one such disorder,
believed to be the results of multiple factors both genetic and environmental. Affecting over 2
million people in the US alone, it has become a major clinical and public health concern worldwide.
This paper gives an update of schizophrenia biomarker research as reviewed by Lakhan in 2006 and
gives us a rundown of the progress made during the last two years. Several studies demonstrate
the potential of cerebrospinal fluid as a source of neuro-specific biomarkers. Genetic association
studies are making headway in identifying candidate genes for schizophrenia. In addition,
metabonomics, bioinformatics, and neuroimaging techniques are aiming to complete the picture by
filling in knowledge gaps. International cooperation in the form of genomics and protein databases
and brain banks is facilitating research efforts. While none of the recent developments described
here in qualifies as biomarker discovery, many are likely to be stepping stones towards that goal.
Background
Schizophrenia is a complex disturbance of mind and
brain characterized by psychotic symptoms such as delu-
sions and hallucinations. In a review of several epidemio-
logical estimates using varied criteria, McGrath et al. [1]
report the worldwide incidence of schizophrenia to range
from 7 to 42 per 100,000 population. In the US alone,
over 2 million Americans have been diagnosed with schiz-
ophrenia [2]. The US Centers for Disease Prevention and
Control (CDC) estimated the national expenditure for
overall mental health in 2003 at over $100 billion.
The history of schizophrenia is obscure possibly due to
the heterogeneous nature of the disorder and consequent
difficulty in formal classification. Earliest case reports date
back to the 1800s [3]. Despite an abundance of research,
the pathogenesis and etiology of this often highly disa-
bling disorder remains unclear. Not surprisingly, the diag-
nosis and treatment of schizophrenia remains
problematic; mainly for the following reasons:
• Diagnosis is solely based on behavioral markers, either
as self-reported symptoms by patients or observations by
clinicians.
￿ No laboratory diagnostic and screening tools are cur-
rently available.
￿ Symptoms may overlap with other neurological and
psychiatric problems such as organic syndromes (e.g.
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drug-induced psychoses, delirium and dementia), psy-
chotic mood disorders and personality disorders.
It would clearly be desirable to identify a diagnostic tool
for schizophrenia that is highly specific, and highly sensi-
tive. Of importance the marker should signify the disease
early in its course, as there is evidence that delays in diag-
nosis and intervention lead to a poorer prognosis. In addi-
tion, a method that is cost-effective and non-invasive
would be of added value [2,4].
Objective of the review
The use of biological markers in medicine has come a long
way with advances in the fields of pathology, biochemis-
try and most notably genetics. For example, prevalent and
debilitating diseases such as heart failure can be diag-
nosed with high sensitivity and specificity by measure-
ment of levels of B-natriuretic peptide (BNP). Certain
types of cancer can be screened for and monitored by spe-
cific tumor markers. Genetic diagnoses can be obtained
for cancers, and numerous other diseases from Parkin-
son's to hypertrophic cardiomyopathy.
In psychiatry, biomarker research is more problematic
due to the difficulty in illuminating the pathophysiology
of psychiatric disorders. Despite this, extensive research
on the genetics and proteomics of neurodegenerative dis-
orders such as Alzheimer's disease (AD) is making head-
way [5]. This article is an update of the paper by Lakhan
[2] and reviews the current status of biomarker research
for schizophrenia, with emphasis on proteomics and
genomics.
Biomarkers
Biomarkers may be in the form of genes, proteins and
other molecules, or morphological characteristics.
Depending on the information they can provide, biomar-
kers may be used in diagnostics as prediction tools (e.g.
subclinical markers, risk or vulnerability markers), or as
diseases signatures (e.g. disease markers, stage or progres-
sion markers) (see Figure 1).
Although the pathophysiology of schizophrenia remains
unclear, there is an increasing body of evidence that sev-
eral molecular pathways are involved. Most findings point
to the direction of malfunctioning of the glutamate path-
way [6]. It is hoped that these molecular processes are mir-
rored in easily detectable biomarkers. However, this is not
the case thus far.
Genes as biomarkers: from genes to symptoms
Genetic studies have attempted to identify genes that pre-
dispose an individual to certain diseases. Examples of cur-
rently used genetic biomarkers are the breast cancer
susceptibility gene 1 (BRCA1) or breast cancer susceptibil-
ity gene 2 (BRCA2).
The genetic basis of psychiatric disorders has, thus, far
proven to be more complex than many other diseases.
Though there is evidence, mostly from simple familial
studies that there are degrees of inheritance in many psy-
chiatric problems, the relationship between genes and
phenotype, and furthermore the penetrance and expres-
sivity of candidate genes is difficult to determine. For
example, individuals showing schizotypal behavior traits
but not overt psychotic symptoms may have a similar
genetic profile to a diagnosed schizophrenic patient, but
the way the genes manifest themselves can be altered by
developmental and environmental factors, i.e. expressiv-
ity. That is assuming that schizophrenia lies on the end of
a continuum with schizotypal personality disorder.
According to Riley et al. [6], schizophrenia is not geneti-
cally determined but rather genetically mediated. Multi-
ple genes of varying effects interact with each other and
with environmental factors to cause the wide spectrum of
schizophrenic symptoms.
Association studies: SzGene database
As previously reviewed by Lakhan [2], genes linked to
schizophrenia are found in several chromosomal regions.
A big step in schizophrenia genomics is the creation of the
SchizophreniaGene (SzGene) database by Allen and col-
leagues [7] to collate all association studies on schizo-
phrenia. It is estimated that over 1000 schizophrenia
genetic association studies have been conducted to date
and SzGene aims to facilitate interpretation of findings
across geographical areas. It also facilitates meta-analyses
of largely inconsistent but still valuable results in schizo-
phrenia genomics, including allele-based meta-analyses
for polymorphic genotype data. These meta-analyses have
already identified more than 20 different candidate genes,
both well-known as well as novel genes [8].
Using the SzGene database, Sun et al. [9] conducted a sur-
vey of over 2000 linkage studies involving 539 candidate
genes for schizophrenia. Using a ranking system based on
combined an odds ratio method, the authors came up
with a set of top ranking genes that future studies may be
able to use as a working blueprint. Among those most
highly ranked are DISC1, DTNBP1, COMT, DAO, RGS4,
NRG1, and GRM3. Below we will look closely at two of
the most promising gene markers for schizophrenia.
The DISC1 gene
One of the most promising of the many risk gene marker
candidates is the disrupted in schizophrenia 1 (DISC1)
gene [10,11]. The DISC1 linkage was initially observed in
extended Scottish families but has now been replicated inBehavioral and Brain Functions 2009, 5:2 http://www.behavioralandbrainfunctions.com/content/5/1/2
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Finnish, American, Japanese, and Taiwanese several pop-
ulations [12].
A SzGene database search listed 24 schizophrenia-associ-
ation studies for DISC1 from 2001 to February 2008. Of
these, 15 were ethnic-based studies and 9 were family-
based. However, most of the studies were based on Cau-
casians and Asians; other ethnic groups are underrepre-
sented. Fifteen studies reported positive association of
DISC1 with schizophrenia.
Evidence, mainly from animal models, supporting the
potential of DISC1 gene as a biomarker, is mounting.
Associations have been found between mutant DISC1
genes and neurocognitive deficit symptoms specific for
schizophrenia and bipolar disorders [12]. DISC1 is
present in regions (i.e. cerebral cortex and hippocampus)
of the brain that shows abnormality in schizophrenia
patients; aberrant DISC1 expression results in reduced
volume of frontal cortical gray matter [12].
The function of the DISC1 gene or its mechanistic role in
schizophrenia is still not fully known and current research
is focusing on filling this knowledge gap.
DTNBP1
Another potentially valuable gene marker for schizophre-
nia is the dystrobrevin-binding protein 1 (DTNBP1), also
known as dysbindin. A SzGene database search for
DTNBP1 revealed 28 case-control association studies and
The pathway to schizophrenia biomarker discovery and clinical applications Figure 1
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16 family-based studies between 2002 and April 2008.
Most studies involved Caucasians, followed by Asians,
though a few studies on mixed ethnicities were also regis-
tered. Of a total of 44 studies, only 18 reported positive
association with schizophrenia.
DTNBP1 is considered to be a modifier gene and has
shown strong evidence of illness modification involving
negative and cognitive symptoms [13]. It was found to
interact with the interleukin 3 (IL3) gene and jointly con-
tribute to schizophrenia risk [14].
Although the search for schizophrenia genetic markers
seems to be making progress, the fact remains that there
are big overlaps in the susceptibility genes between schiz-
ophrenia and other psychotic and mood disorders [15].
This problem of specificity needs to be resolved before
these genes can be routinely used for genetic screening for
schizophrenia.
Endophenotypes
It is believed the number of genes involved in a phenotype
increases with the phenotype's complexity, thus, increas-
ing the complexity of genetic analysis as well [16]. The fact
that schizophrenia is a pleiotropic disorder multiplies the
complexity several fold. The endophenotype approach in
psychiatry aims toward a more tractable and objective
diagnosis of psychiatric disorders using genetic analysis.
Endophenotypes are heritable trait-related deficits meas-
urable by laboratory-based diagnostic tools rather than by
clinical investigations [17]. An endophenotype may be
neurophysiological, biochemical, endocrinological, neu-
roanatomical, cognitive, or neuropsychological symp-
toms and would include configured self-report data.
Several candidate endophenotypes such as working mem-
ory, oculomotor function, sensory motor grating, and
glial cell abnormalities have been linked to certain gene
regions [16].
An example of using oculomotor function as a trait or
state marker in neurological disorders has been described
by Chen et al. [18]. Dysfunction in visual processes such
as eye tracking, visual backward masking, motion percep-
tion, and contrast detection were observed in patients
with schizophrenia and bipolar disorder.
Bender et al. [19] reviewed common early recognition
instruments for psychosis in the context of endopheno-
types that included P300, P50 sensory gating, mismatched
negativity, smooth pursuit eye movements.
Endophenotypes in the form of cognitive neuroimpair-
ments such as prospective memory deficit [20,21], and
visual and verbal memory deficits [22] have also been
described for patients with schizophrenia.
In summary, in the field of genomics, progress is being
made in several fronts. In the case of association studies,
all ethnic groups should be represented for data to be
more meaningful. Currently, the number of schizophre-
nia candidate genes is too large; priority should be given
to identifying the most relevant genes, especially those
linked to endophenotypes. It has also been suggested that
whole-genome association studies can reveal the genetic
modifiers of schizophrenia [13].
Proteomics: from genes to proteins
It is not the presence of certain proteins per se that make
them markers but rather their expression, the shifts in
expression as well as their state. In many cases, however,
it is not just one protein but a set of proteins that is indic-
ative of a disease. Using breast cancer as example, the
most common diagnostic molecular biomarkers for this
disease are estrogen receptor (ER), progesterone receptor
(PR), and HER2/neu proteins.
A primary challenge in the search for biomarkers is easy
access to sufficient amounts of high-quality tissue or body
fluids [23]. Sources of biomarkers are the blood, urine,
cerebrospinal fluid (CSF), and certain tissues.
Biomarkers in blood
Diagnostic tests using blood sample is standard in clinical
practice. As source of biomarkers, it has the advantage of
easy and standardized collection procedure, and can be
available in sufficiently large volumes. However, blood-
based specific biomarkers for schizophrenia are still elu-
sive.
Bibl et al. [24] report that the ratio of Aβ1–38/Aβ1–40
peptides in the plasma of patients with dementia may be
a potential diagnostic tool. Another study [25] identified
18 signaling proteins in blood plasma of patients with
AD. These proteins were used in blinded identification
with almost 90% accuracy.
Serum levels of the inflammatory markers sTNFR1 and
sTNFR2, (soluble receptors of the tumor necrosis factor)
were found to be higher in chronic institutionalized
patients with schizophrenia than in control individuals.
However, no correlation with symptom severity was
found [26].
Dietrich-Muszalska and Olas [27] looked at the role of
oxidative stress in schizophrenia patients as manifested in
blood platelet aggregation in response to known platelet
agonists such as ADP and collagen. Collagen-stimulated
platelet aggregation was significantly lower in the patientBehavioral and Brain Functions 2009, 5:2 http://www.behavioralandbrainfunctions.com/content/5/1/2
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group than in the healthy controls. ADP-induced aggrega-
tion on the other hand, was significantly higher.
In another study [28], the activity of the platelet antioxi-
dative enzyme superoxide dismutase (SOD), and the lev-
els of thiobarbituric acid reactive species (TBARS) were
measured as oxidative stress indicators. Results suggested
an enhanced generation of reactive oxygen species and
significantly lower SID activity in schizophrenia patients
compared to healthy controls.
The telomere length in the peripheral blood lymphocytes
(PBL) of individuals with schizophrenia has been
observed to be significantly reduced. In a follow-up study,
Porton et al. [29] quantified the activity of the enzyme tel-
omerase in PBL and found a nominally significant
decrease in telomerase activity in individuals with schizo-
phrenia compared to unaffected individuals.
Biomarkers in urine
Urine has proven to be an invaluable source of biomark-
ers for many urological, gynecological and metabolic dis-
orders and infections. It has the advantages of being
available in large amounts, collection is non-invasive, and
it remains stable for extended periods [29]. On the down-
side, protein content in urine is highly variable and rela-
tively low, and salt content is high compared to other
body fluids [30,31]. Except for very few studies, this
source has proven to have limited success in the neuropro-
teomics of psychiatric disorders.
Indicators of oxidative stress are detectable in the urine.
Significantly increased levels of isoprostanes were
observed among schizophrenia patients relative to the
controls, as measured by isoprostane-8-epi-prostaglandin
F(2alpha) (8-isoPGF(2alpha)) concentrations in the urine
[32]. Oxidative damage by free radicals and the measure-
ment of isoprostanes in the urine of AD patients have
been previously described [33].
Another study [34] measured concentrations of biopyr-
rins, metabolites of bilirubin oxidation, in the urine of
patients with schizophrenia and depression. Biopyrrin
values of schizophrenia patients significantly correlated
with Brief Psychiatric Rating Scale (BPRS) scores. For
patients with depression, biopyrrin values correlated sig-
nificantly to the Hamilton Depression Rating Scale
(HAM-D) scores.
Biomarkers in the cerebrospinal fluid
Because of its proximity to the affected tissues of the nerv-
ous system, it seems logical that the chemical properties of
the cerebrospinal fluid (CSF) would more closely reflect
pathophysiological alterations caused by neurological
disorders than any other body fluids.
The use of CSF as standard biomarker source is however,
a subject of controversy. There are those who perceive the
sampling procedure through lumbar puncture as invasive
and risky for the patient. CSF collection is not a standard
clinical procedure in many countries and may therefore
require obtaining informed consent, a process that is com-
plicated by the mental status of the patients concerned
[35,36]. Others claim that CSF can be very variable
depending on collection procedure, storage, and time of
the day [23]. However, there are also studies which report
lumbar puncture to be safe and acceptable even in
patients of mixed cognitive status [37,38].
Still, CSF-based neurochemical diagnostics look very
promising in many neurological disorders including AD
[5,39] and amyotrophic lateral sclerosis (ALS) [40].
Increased tau and decreased Aβ42 have been validated as
AD disease markers [41]. In a recent study, Zhang et al.
[42] reported a CSF-based multianalyte profile that can
distinguish between AD and Parkinson disease.
Huang et al. [35] detected characteristic profiles of pep-
tides and proteins in CSF of schizophrenia patients which
are potentially specific for schizophrenia. Using the latest
mass spectrometric approaches (see methodological
review [2]), they detected significant changes between
protein/peptide profiles of drug-naïve schizophrenia
patients compared to demographically matched healthy
controls. The key fragments were a 40-amino acid long
VGF-derived peptide sequence, a transthyretin protein
cluster, and another partly characterised smaller cluster
related to transthyretin. A simple and controlled method
for CSF-biomarker discovery is described by Huang et al.
[36].
To test for specificity, the alterations were compared with
CSF samples from patients with similar neurological con-
ditions. They were found to be specific for patients with
schizophrenia, slightly similar for patients with depres-
sion but very distinct from patients with OCD or AD. The
authors [36] report 95% specificity and 80 to 88% sensi-
tivity in the two sets of experiments. Limitations of the
study include the small number of samples especially
those of non-schizophrenia psychosis patients.
Biomarkers in brain tissues
Miller et al. [43] looked at the metabolites of the kynure-
nine pathway in post-mortem brain tissues of patients
with schizophrenia and bipolar disorder. The precursor
tryptophan was higher in the schizophrenia group; the
end-product nicotinamide did not differ significantly
between patient groups and controls. In a follow-up
study, Miller and Dulay [44] looked at niacin receptors
and reported that the protein for HM74A receptors was
significantly lower in the schizophrenia group, while tran-Behavioral and Brain Functions 2009, 5:2 http://www.behavioralandbrainfunctions.com/content/5/1/2
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scription for the protein increased. No significant differ-
ences were observed between the bipolar disorder group
and controls. The studies presented some potentially
highly specific biomarkers than need to be confirmed in
biofluids.
One of the criteria for an ideal diagnostic biomarker for
AD is validation against autopsy-proven cases [4]. How-
ever, Ranganathan et al. [45] report big differences
between the protein profile of CSF from live patients with
amyotrophic lateral sclerosis (ALS) and that of post-mor-
tem brain tissues.
A significant step forward in biomarker research is the
establishment of brain banks or biorepositories that col-
lect post-mortem brains and CNS tissues for research pur-
poses [46-50] although the initiative is rife with
controversies regarding legal and bioethical issues.
In summary, CSF is probably the most promising source
of biomarkers, followed by blood. There is, however, a
great need for standardization of study designs and meth-
ods. Comparison of proteins found in the blood and the
CSF would be a step in the right direction. There are
already indications that certain biomarkers are trans-
ported from plasma to CSF and vice versa [51] but these
need to be confirmed by more extensive studies.
Bioinformatics: bridging genomics and proteomics
Current studies are focusing on protein expression and
protein-protein interactions (PPI) around certain genes to
bridge the knowledge gap between genomics and pro-
teomics. Through bioinformatics, a network of protein-
protein interactions around the DISC1 gene was gener-
ated, the so-called "DISC1-Interactome" [11,52]. The
interactome came up with 2 potential DISC1-related pro-
tein candidates, the NDEL1 (nudE nuclear distribution
gene E homologue-like 1) and phosphodiesterase 4B
(PDE4B), a cAMP signalling-specific phosphodiesterase
[52]. NDEL1 may function both as a cysteine protease and
a key centrosomal structural protein. With its interaction
with DISC1, it is said to significantly influence the risk for
schizophrenia [53]. PDE4B is an independently identified
risk factor for schizophrenia [54].
Like DISC1, a similar interactome for DTNBP1 has now
also been generated [55].
Researchers in Taiwan [56] have recently set up Phos-
phoPOINT, an open-access comprehensive human kinase
interactome and phospho-protein database. It basically
integrates the characteristics of the abovementioned pro-
teins, their PPI datasets, substrates, interactions, gene
expression and ontology, as well as their single nucleotide
polymorphisms (SNPs), and their role in human diseases.
Linked phenotypes in the database include schizophrenia
and hypertension.
Metabonomics: metabolic pathways and metabolites
The controlled metabonomics study by Holmes et al. [57]
investigated the metabolic profiles of CSF collected from
patients with first-onset schizophrenia not treated with
any antipsychotic drugs. The metabolic state of CSF was
determined through glucoregulatory processes and their
metabolites. Glucose levels in the CSF of drug-naïve
patients show highly significant increased glucose levels
compared to health control subjects. These elevated CSF
glucose levels were not reflected in blood glucose levels,
indicating a central nervous system-specific process.
Subsequent tests by the same group of researchers showed
that short-term therapy using atypical antipsychotic drugs
has the tendency to normalize of the CSF metabolic pro-
file among patients with schizophrenia. The normaliza-
tion was detectable well before clinical symptoms overtly
improved. This study suggests that the products of gluco-
metabolic process in the CSF can be used as a disease
marker for first-onset paranoid schizophrenia.
Limitations of the study are the small number of patients
in some of the treatment groups and the popular use of
cannabinoids among patients with schizophrenia, which
may have affected metabonomic measurements.
Metabonomics is a relatively new field of research. It is
perceivable that data on metabolic processes can contrib-
ute to the understanding of the pathophysiology of schiz-
ophrenia.
Neuroimaging: from genes to morphology and function
Neuroimaging has been invaluable in studying the struc-
ture and function of the brain. It also has a great potential
for the diagnosis and treatment and neuropsychiatric dis-
orders.
Using cognitive paradigms, functional magnetic reso-
nance imaging (fMRI) studies have shown changes in cer-
ebellar activity in patients with schizophrenia, anxiety
disorders and dementia (see review [58]).
In a twin pair study [59], abnormalities in proton mag-
netic resonance spectroscopy (1H MRS) neurometabolites
glutamate, creatine plus phosphocreatine (Cr), glycero-
phosphocholine plus phosphocholine (Cho), and N-
acetylaspartate were not present in control individuals but
present in both schizophrenia-affected and unaffected
twins, although the levels were significantly higher in the
affected twin. This indicates that these abnormalities can
be used as trait markers as well state markers of the disor-
der.Behavioral and Brain Functions 2009, 5:2 http://www.behavioralandbrainfunctions.com/content/5/1/2
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Kubicki et al. [60] observed significant reduction in inter-
hemispheric brain connectivity in the corpus callosum of
individuals with schizophrenia using the diffusion tensor
imaging techniques.
Recent research studies used neuroimaging techniques in
linking genes to brain morphology and function. One
such study by Windemuth et al. [61] identified endophe-
notypes associated with schizophrenia. They found 3 sin-
gle nucleotide polymorphisms in certain genes were
significantly associated with fMRI activity.
Giedd et al. [62] proposed that changes in brain morphol-
ogy over time as measured by neuroimaging techniques
may be used as endophenotypes for neurological disor-
ders. These so-called brain trajectories may be used as
markers that bridge the gap between genes and behavior.
Using MRI, Takahashi et al. [63] investigated the associa-
tion between brain morphology and gene polymorphism.
Their results indicate that high-risk genotypic combina-
tions affect brain morphology, particularly the posterior
hippocampus.
These latest developments show that neuroimaging is
invaluable in linking brain function and activity to form.
However, more studies focused on the schizophrenic
brain and how it is linked to disease-specific genes or gene
regions are needed to link trait markers to biomarkers.
Discussion and conclusion
This article attempts to review the most significant find-
ings in the field of schizophrenia biomarker research dur-
ing the last two years. While none of the developments
described here qualify as biomarker discovery, many will
likely serve as stepping stones towards that goal. To sum-
marise the major achievements:
￿ There has been a rapid increase in schizophrenia
research; current publication rate as estimated by SzGene
databases is 90 papers a week [7].
￿ Genetic studies have definitely made headway in screen-
ing for candidate schizophrenia genes in association stud-
ies. Endophenotypes or intermediate phenotypes are
useful in the understanding the pathway from genes to
behavior.
￿ Schizophrenia proteomics lags behind compared to
other neurological disorders such as AD. However,
progress has been made in identifying candidate protein
and metabonomic markers. CSF as a source of disease
markers looks especially promising as demonstrated in
the case of AD.
￿ Neuroimaging is also making progress in linking geno-
types to brain morphology, supporting the endopheno-
type approach.
￿ International cooperation in the form of networks, open
access databases and brain banks is facilitating compari-
son and verification of results.
However, there is still a long way to go before biomarkers
become part of the standard clinical care for schizophre-
nia patients. Before we get there, there are several things
that need to be improved upon, as follows:
￿ We need to conduct larger studies for more statistical
power.
￿ Candidate biomarkers need to be tested for sensitivity
and specificity to resolve overlaps with related disorders.
￿ More association studies are needed, especially those
looking at other ethnic groups besides Caucasian.
￿ Methods for sample collection, storage, and sample
processing of biofluid sources of biomarkers, especially
CSF, need to be standardized.
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